Serial entrepreneur Alfred E. Mann notified the MannKind Corp. of Santa Clarita that he was resigning as Executive Chairman and board member effective immediately on Feb. 17. No reason was given.
The next day MannKind’s board of directors named Kent Kresa as Chairman of the Board and also named Mann as Chairman Emeritus of MannKind. Mann will continue to advise the company as an employee in a non-executive capacity.
"Al founded this company in order to bring his unique flair for medical innovation to the biopharmaceutical space," CEO Matthew Pfeffer said in a statement. "We are awed by his many accomplishments during a legendary career and are proud to continue Al's decades-long pursuit of addressing the unmet needs of patients with diabetes and other serious illnesses."
After years of research, development, and clinical trials, MannKind’s new delivery system for the treatment of diabetes, Afrezza - an inhaled insulin product - was approved by the Food and drug Administration in 2014. A partnership with a Paris-based marketing and distribution fizzled and the agreement was terminated Jan. 5.
Born in the mid-1920s in Portland, Oregon, Mann’s ability to envision new realities first led him to found companies in the aerospace industry setting up companies that were later successfully sold to Boeing and Textron. But, he soon entered the biomedical industry founding and funding Bioness, Second Sight, IncuMed, PerQFlo, MiniMed, Second Sight, Advanced Bionics and Manknkind. He also founded Quallion and Stellar Microelectronics to service the aerospace field. Overall, he has founded and largely funded 14 companies, several of which operate in Santa Clarita. The Mann Biomedical Park bears his name, as well as the Alfred Mann Foundation in Valencia.
"Al is a true visionary and has created a great company with an impressive lead product and powerful technology to help patients with serious diseases," Kent Kresa, Chairman of MannKind Corp. said in a statement. "We have much to do to make his dreams a reality, but we have the people, technology and know-how to make that happen."
Kresa has been a director of MannKind since June 2004 and was named Lead Director in November 2011. Kresa is also Chairman Emeritus of Northrop Grumman Corporation, having previously served as its Chairman and CEO.
